Cost of epilepsy meds continues to soar
Costs for epilepsy medications in the United States are skyrocketing, outpacing inflation and straining federal insurers Medicare and Medicaid, according to new research.
Dec 2, 2022
0
8
Costs for epilepsy medications in the United States are skyrocketing, outpacing inflation and straining federal insurers Medicare and Medicaid, according to new research.
Dec 2, 2022
0
8
Continuous glucose monitoring (CGM) is associated with improved health outcomes for patients with diabetes. Primary care practices, however, have been slow to adopt the technology. Researchers used a web-based survey to assess ...
Nov 29, 2022
0
2
An analysis by researchers at City of Hope, one of the largest cancer research and treatment organizations in the United States, found that cancer patients with privatized, cost-saving Medicare Advantage were more likely ...
Nov 21, 2022
0
61
For nearly 10 years, Stacie Dusetzina, Ph.D., a Vanderbilt University professor of Health Policy and Ingram Professor of Cancer Research, has focused her research on one core policy issue that has been of interest to lawmakers ...
Nov 3, 2022
0
2
A new study published in today's issue of the Journal of the American Medical Association (JAMA) analyzes the benefits and harms of prior authorization (PA) policies for Medicare and the impact these policies have on patients ...
Oct 3, 2022
0
6
UNC School of Medicine's John Batsis, MD, and UConn's Patrick Coll, and colleagues authored an analysis of Medicare's Annual Wellness Visits since they were instituted 10 years ago, finding the one-size-fits-all approach ...
Sep 7, 2022
0
22
President Joe Biden on Tuesday signed the Inflation Reduction Act into law, making it the most significant health care legislation enacted in more than a decade.
Aug 17, 2022
0
5
Large dialysis chains charge Medicare Advantage plans 27% more for dialysis services compared with what they charge the traditional, fee-for-service Medicare program, according to a new USC analysis.
Aug 2, 2022
0
2
Medicare could waste up to $605 million per year on the controversial Alzheimer's drug aducanumab if it is eventually approved for widespread use because it is supplied in vials containing fixed doses that may not be appropriate ...
Jun 27, 2022
1
13
A brief research report found that Medicare could have saved up to $3.6 billion by purchasing generic drugs at the same prices as the Mark Cuban Cost Plus Drug Company (MCCPDC) in 2020. These findings suggest that Medicare ...
Jun 20, 2022
0
32